Curi Bio Launches Asia-Pacific Hub, Delivering Greater Support to its Growing APAC Business

SEATTLE--(BUSINESS WIRE)--Curi Bio, the leader in delivering human-relevant functional data for drug discovery and development, today announced the formal establishment of Curi Bio Co., Ltd. a wholly-owned subsidiary, following the full acquisition of Quvit Bio of South Korea. The new subsidiary will serve as Curi Bio’s commercial and operational hub in the Asia-Pacific (APAC) market, significantly expanding its direct presence and scientific capabilities to serve its growing customer base.

“Establishing direct operations in Korea and integrating Quvit’s talented team is a pivotal moment that accelerates our global strategy,” said Dr. Nicholas Geisse, CEO of Curi Bio. “Curi Bio Co., Ltd. represents a day-1 ready sales, R&D, and operational hub, allowing us to directly serve the APAC market. We can now offer localized technical and sales support for our existing customer base across South Korea, Japan, and China while lowering the access barrier to Curi’s industry-leading NAM technology for all drug developers in the region. In addition, the establishment of a local operations hub ensures that we can deliver our cells, media, hardware, and consumables products with minimal delays due to international logistics. This signals our commitment to providing human-relevant preclinical data to guide business decisions that speed next-generation medicines to market across the globe.”

Global Infrastructure and Key Leadership

The strategic move includes the acquisition of Quvit Bio’s assets and team, bringing immediate expertise in regional sales, business development, hardware and software engineering, and life science tools. Curi Bio Co., Ltd. is a full-service hub, going beyond business development and immediately providing technical and sales support to APAC customers across Curi’s product and services portfolio.

Curi Bio Co. Ltd. will be represented by Dr. Wonil Lee, who was appointed VP of Research and Commercialization at the company. Dr. Lee will serve as the central point of contact for existing and future customers.

About Curi Bio

Curi Bio is a leading developer of human stem cell-based platforms for drug discovery and development. The company’s integrated platform—The Curi Engine™—combines human iPSC-derived cell models, advanced tissue-specific biosystems, and AI/ML-enabled phenotypic screening data to accelerate the discovery of new medicines. Curi Bio partners with global biopharmaceutical companies to provide clinically-relevant, human data to inform R&D decision-making and decrease the industry’s reliance on poorly predictive animal models. For more information, please visit www.curibio.com.